Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib for advanced rare cancers
ChiCTR2400086153Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in rare cancer, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Jun 2024; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
rare cancer
Beyond the preview
Go deeper on ChiCTR2400086153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086153.